Volume 28, Number 4—April 2022
Research
SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil
Daniel Gonçalves Chaves1
, Ricardo Hiroshi Caldeira Takahashi1, Felipe Campelo, Maria Clara Fernandes da Silva Malta, Isabelle Rocha de Oliveira, Edel Figueiredo Barbosa-Stancioli, Maísa Aparecida Ribeiro, and Marina Lobato Martins
, Ricardo Hiroshi Caldeira Takahashi1, Felipe Campelo, Maria Clara Fernandes da Silva Malta, Isabelle Rocha de Oliveira, Edel Figueiredo Barbosa-Stancioli, Maísa Aparecida Ribeiro, and Marina Lobato Martins
Table
Characteristics and severe acute respiratory syndrome coronavirus 2 IgG seroprevalence among blood donors, Brazil, March–December 2020
| Characteristics | Total samples | Positive samples | Unadjusted seroprevalence, % (95% CI) | Test-adjusted seroprevalence, % (95% CI)* | Odds ratio (95% CI) |
|---|---|---|---|---|---|
| Total |
7,837 |
441 |
5.6 (5.1–6.2) |
5.2 (4.7–5.8) |
|
| Sex | |||||
| M | 4,284 | 273 | 6.4 (5.7–7.1) | 6.0 (5.3–6.9) | 1.4 (1.1–1.6) |
| F |
3,553 |
168 |
4.7 (4.1–5.5) |
4.2 (3.5–5.0) |
|
| Age range, y | |||||
| 16–30 | 2,895 | 153 | 5.3 (4.5–6.2) | 4.8 (4.0–5.8) | |
| 31–40 | 2,330 | 135 | 5.8 (4.9–6.8) | 5.4 (4.4–6.5) | |
| 41–50 | 1,701 | 115 | 6.8 (5.7–8.1) | 6.5 (5.3–7.9) | |
| 51–60 | 829 | 32 | 3.9 (2.8–5.4) | 3.2 (2.0–4.9) | |
| 61–70 |
82 |
6 |
7.3 (3.4–15.1) |
7.1 (2.7–15.8) |
|
| Donor type | |||||
| First-time donor | 1,483 | 72 | 4.9 (3.9–6.1) | 4.3 (3.2–5.7) | 0.8 (0.7–1.1) |
| Repeat donor | 6,353 | 369 | 5.8 (5.3–6.4) | 5.4 (4.8–6.1) |
*Considering sensitivity of 90% and specificity of 99%. Analysis performed by Epitool by using Wilson’s confidence interval for apparent rate of positivity and Blaker’s CI for true rate of positivity.
1These authors contributed equally to this article.
Page created: February 09, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.